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Abstract 
Close control of blood glucose levels significantly 
reduces vascular complications in diabetes, as well as 
having beneficial effect for cardiac and other critical 
care patients. Recent studies have shown that tight 
regulation of blood glucose level in intensive care unit 
patients can reduce mortality by as much as 45%. This 
paper presents an optimal insulin infusion algorithm to 
tightly regulate blood glucose for ICU and other 
critical care patients when the glucose input is known. 
Results show an ideal, flat blood glucose response 
when subjected to a typical ICU glucose input as well 
as for a far more extreme case. 
 
1. Introduction 
 
Hyperglycemia and insulin resistance are common in 
critically ill patients, even if they have not previously 
had diabetes. The normalization of blood glucose 
levels with insulin therapy to far tighter levels than 
normally employed has recently been seen to improve 
the mortality of ICU patients by as much as 45% [1]. 
Specifically, the use of a 4-hour bandwidth blood 
glucose monitoring and insulin therapy regime has 
been found to reduce mortality in critical care patients. 
The methodology restricted blood glucose levels to 
approximately 5.8 mmol/L, the maximum level 
typically desired by diabetes clinicians. Normal critical 
care blood glucose management will often allow for 
levels two times this value, with potentially increased 
patient risk. 
 
Ambulatory diabetic individuals monitor food intake 
and daily activity to maintain blood sugar levels at an 
adequate level.  In the ICU case patients are often 
hyperglycemic with no previous history, due to the 
stress the entire bodily system is undergoing. As a 
result, this condition can be far different from an 
ambulatory diabetic individual as ICU feeding, while 
variable in some cases, provides a known glucose input 
profile to a patient with a measurable insulin resistance. 
However, in each case high blood glucose levels must 
be tightly regulated using insulin therapy. 
 
Though devices that can measure glucose level and 
administer insulin exist, they do just that – measure and 
inject - with no automated interface between the two.  
ICU patients typically have their blood glucose 
monitored 2-6 times per day and are treated with 
insulin by a standard protocol to minimize blood 
glucose excursions. 
 
Most commonly available glucose sensing devices 
operate by measuring the blood glucose content of a 
small finger-prick blood sample, an irritating method 
upon frequent use. However, recent advances in 
technology suitable for ICU patients has been 
developed that enable blood glucose measurement at 
rates from every 0.6-7.0 minutes [2-4]. With time 
constants on the order of minutes the faster of these 
rates are essentially continuous measurement. This 
rapid measurement enables feedback control, with 
knowledge of the glucose input, to be applied to 
minimize blood glucose levels toward the basal rate of 
4.5-5.0 mmol/L, eliminating the exposure to elevated 
blood glucose levels and the damage that can result. 
 
Typically, relaxed higher blood glucose levels are 
considered acceptable, as blood glucose management 
without automation does not typically deliver the data, 
or the ability to constantly modify insulin infusion rates 
to achieve tighter control. However, regular, automated 
blood glucose measurement provides the consistent 
volume of data necessary for such tight control, in 
contrast to the sometimes infrequent and inconsistent 
efforts available in busy critical care units. The ideal 
response would be a flat line at the basal level [5]. 
 
Whether it is in the area of understanding, modeling or 
managing diabetes [6,7] years of research in this area 
has led to no shortage of potential solutions [8-17].  
However, due to either the complexity of the proposed 
implementation, current technological limitations, 
models that are not physiologically verified, lack of 
required data, or the cost/complexity of realizing the 
results, these solutions are not yet fully practicable.  
 
Several researchers have examined the analysis and 
automation of insulin as reviewed by Lehman et al. 
[18]. Many of the systems presented use control as a 
means of providing clinical advice or testing the 
efficacy of a new protocol [19-24]. A more complex, 
higher performance real-time control example uses 
model predictive control on a 19th order system 
identified model resulting in a 40% peak reduction and 
23% reduction in settling time [25]. Optimal control 
using grid search theory, robust H-infinity control, and 
  
variable structure controllers have also been studied, 
each using different models [11, 24-28]. However, the 
models used typically require either patient specific 
parameters that are not generically available and/or 
knowledge of glucose or exercise inputs that would not 
be known a priori. Finally, none study the impact of 
more frequent measurement enabled by recent 
advances in sensing technology or the potential for 
improved results in specialized, controlled cases such 
as the ICU. 
 
This research develops the equations necessary for 
real-time steady-state optimal control of blood glucose 
excursions from the basal level. The control laws are 
derived from a basic model of the essential dynamics 
of the non-linear, multi-compartment glucose-
regulatory system, and take advantage of the 
knowledge of the glucose input profile available in 
ICU and other critical care settings. The system is 
verified numerically and compared to normal, modeled 
human response to the same inputs, which recent 
studies have shown to be similar to PD slope control of 
blood glucose level [29].  
 
 
2.  Dynamic System Model  
 
Comprehensive models, though they are very accurate 
in regimen evaluation, are generally unsuited for real-
time control, requiring several time points of input to 
generate the insulin infusion profile. Additionally, they 
are not generic requiring patient-specific data and 
known glucose inputs.  The aim of this research is to 
develop control schemes based on models that capture 
the essential system dynamics, do not require 
unavailable data, and are applicable to a wider variety 
of subjects. Simple models capture these essential 
dynamic behaviours, providing a more suitable 
foundation for real-time control design and analysis 
that can be applied to a broad range of patients.  
 
A well known, and more importantly, physiologically 
verified model originated from the work of Bergmann 
et al. [15]. It utilises the concept of a remote 
compartment for the storage of insulin to account for 
the time delay between injection of insulin and its 
utilization to reduce blood glucose levels.  Equations 
(1)–(3) show the equations used to define the system.  
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Where G is the plasma glucose concentration over 
basal (mMol L-1), GB is the basal plasma glucose (mMol 
L-1), X is the generalized insulin variable for the remote 
compartment (min-1), I is the insulin concentration 
above basal (mU L-1), IB is the basal insulin level (mU 
L-1), P(t) is the external glucose input (mMol L-1 min-1), 
u(t) is the external insulin input (mU L-1 min-1), p3  is a 
patient parameter (mU-1 L min-2), VI is the insulin 
distribution volume (L), and n, p1, p2  are patient 
specific parameters (min-1). The parameters, p1, p2 and 
p3, may be changed to represent different conditions of 
the glucose regulatory system. For Type I diabetic 
individuals: p1 = 0, p2 = 0.025, p3 = 0.000013 as 
obtained from medical research [10,13,15]. 
 
The model is simple, yet accurately represents the 
essential dynamics of the human glucose regulatory 
system. The three equations represent insulin infusion 
dynamics, storage in a remote compartment, and 
glucose input and insulin utilization in a second 
compartment. The values of n, VI, GB, IB employed are 
defined, for an average-weighted male as: VI = 12 L, n 
= 5/54 min-1, GB = 4.5 mmol L-1, IB = 15 mU L-1 [10]. 
 
Most reported controllers use a simple feedback loop 
that employs the blood glucose level above basal, G, 
and more rarely its' derivative, , as sensor inputs, and 
the exogenous insulin infusion rate, u(t), as the control 
output.  These controllers measure the output from 
Equation (1) while directly influencing Equation (3) 
via the control action. In between these two equations 
is the time delay and dynamics of the remote 
compartment defined in Equation (2). 
 
 
3.  Derivation of Optimal Control 
 
 
There are many complex influences between glucose 
and insulin concentration for any person, normal or 
diabetic. However, the steady state glucose 
concentration in the body is finally a function of how 
much insulin is present.  The goal is to minimise excess 
glucose, G, and its rate of change, G , and ensure that 
excursions from the basal value, Gb, are minimised in 
magnitude and duration with no hypoglycemic 
overshoot below the basal level. Ideally, blood sugar 
levels should be maintained in a tight range around the 
basal level, varying with glucose input, or feeding, 
level. This approach trends toward the concept that the 
ideal blood glucose curve should be relatively, if not 
completely, flat at G(t)=0. 
 
The optimal solution for u(t) can be obtained 
analytically for the steady-state case where =0 is the 
desired condition that allows the optimal u(t) that 
results in G=0 to be determined.  
 
First, Equation (3) is solved and the exact solution for 
I(t) determined in terms of the exogenous insulin 
infusion u(t).  
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Similarly, using Equation (2), the solution for X(t) is 
obtained in terms of I(t) and, using Equation (4), 
directly expressed in terms of u(t). 
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(5) 
Since the goal is to minimize G to approach or equal 
zero, the assumption of 0== GG   at steady state is 
applied to Equation (1) to obtain a steady state optimal 
solution, from the remaining terms: 
  
)()( tXGtP B=     (6) 
 
More specifically, setting =0 is a means of obtaining 
the optimal solution for u(t) to obtain any desired 
function or value of G. Since we desire, in the steady 
state that G=0, the resulting exogenous insulin input, 
u(t), can be determined from Equation (6), using the 
expression for X(t) in terms of u(t) from Equation (5). 
Note that if the patient is a diabetic and p1=0, the same 
result is obtained. 
 
Substituting Equation (5) into Equation (6) and using 
the Laplace transform and its inverse, to simplify the 
convolution integrals and algebra, the optimal steady 
state exogenous insulin infusion function solution for 
u(t) is obtained: 
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 (7) 
The optimal solution includes first and second 
derivatives of the exogenous glucose input P(t), as 
might be expected in solving a series of two first order 
differential equations to obtain the algebraic solution 
the third equation in Equation (6).  However, it is 
unrealistic to implement in cases where P(t) is not 
known a priori. Since u(t) can become negative it may 
be necessary to infuse additional glucose of the first or 
second derivatives of P(t) are significantly negative in 
value. Equation (7) is also an explicit function of the 
time constants and other model parameters subjecting it 
to potential modelling error. This solution does act as a 
benchmark for the performance of other controllers, as 
well as being suitable for cases where the glucose input 
is well known and controlled, such as in critical care 
and other managed care settings.  
 
Note that the steady-state insulin infusion without 
exogenous glucose input, u(t)=nVIIB=u0, corresponds 
to the result obtained from Equation (7) if  P(t) = 0. 
Since u0 is the basal infusion rate of insulin in the 
absence of glucose input this result serves as a basic, 
but essential, check on the optimal control law derived.  
More specifically, it implies that the optimal control 
law reverts to the basal infusion when there is no 
exogenous glucose input, as should be expected. 
 
This optimal solution will provide an optimal insulin 
infusion profile for any case where the initial 
conditions match the steady state assumptions. It also 
does not employ blood sugar feedback, being a closed 
form solution with knowledge of the glucose input, as 
most previously reported literature. However, 
knowledge of the input limits the solution to 
specialized cases, such as the ICU. 
 
 
4. Numerical Tests and Verification 
 
4.1 Slow Infusion of Glucose 
 
Feeding protocols for ICU patients vary by country and 
region. However, the typical feeding protocol typically 
consists of a very low number of calories being slowly 
infused. The infusion is either (nearly) continuous, or 
given over a 1-3 hour period, 2-4 times daily. 
 
Figure 1 shows the glucose response for a 400 calorie 
input infused gradually over 150 minutes for both a 
normal, non-diabetic response and for the optimal 
infusion for a diabetic individual, which is an ideal flat 
line. Note that the optimal result is not truly flat and 
G(t) varies between G = +/- 0.01 mmol/L, as shown in 
Figure 2. Figure 3 shows the insulin input profiles for 
both cases. Note that the optimal insulin infusion 
profile is essentially an injection at the first part of the 
feeding period and that the area under the optimal and 
normal curves, representing the total insulin infused, is 
approximately the same. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Glucose response to slow infusion. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Optimal glucose response (scaled view). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Insulin response to slow infusion. 
 
4.2 Multiple Meal Glucose Input 
 
The oral glucose tolerance test (OGTT) is a large step 
input test of the glucose regulatory system often 
performed to diagnose diabetes.  A fasting subject 
consumes 400–800 calories of glucose and the 
response is observed. The OGTT input may be 
modelled by using the lognormal distribution defined 
in Equation (8). 
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Where Pm is the peak value and a, b and c are 
constants, which determine the slopes and curvature.   
 
A multiple meal glucose input can be constructed from 
this form of input. The specific input is designed to be 
extreme and its inputs vary in magnitude from 50-400 
calories in two groups, at t = 0,10,30 minutes and at t = 
210 and 300 minutes. At the end of 6 hours, the total 
intake of glucose into the body is over 1000 calories 
with 1000 calories input over the first 4 hours.  
 
As seen in Figure 4, the input profile provides an 
extreme test with large variations over time that are 
significantly greater than what is typically encountered 
in an ICU setting to provide a very rigorous test. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Multi-meal glucose input profile. 
 
The response of the optimal controller to this system as 
well as the modelled normal human response is shown 
in Figures 5 and 6. Figure 5 presents the glucose 
response over basal level, G, for normal, non-diabetic 
and optimally controlled diabetic individuals.  Figure 6 
shows the insulin infusion rate for the same cases.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Glucose response to large multi-meal input. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Insulin response for multi-meal input. 
  
 
Figure 5 has the same essentially flat glucose response 
for the optimal case, as it did for the slow infusion. 
However, the cost of obtaining this response is seen in 
Figure 6, where the insulin response for the optimal 
case consists of steep, sudden infusions that mimic 
injection profiles as each feeding infusion starts. 
However, due to the very steep slopes involved in the 
input there are times where small infusions of extra 
glucose would be required given the demand for 
"negative" insulin in the figure. This limitation of the 
optimal result can be quantified by the demand for 
what are essentially insulin injections of 1-3U followed 
in the two largest cases by small glucose infusions to 
account for the demand for 0.3U withdrawals of insulin 
from the subcutaneous area. The normal insulin 
response in Figure 6 is shaped very much like the input 
itself, as would be expected although it appears flat in 
the figure. 
 
4.3 Summary of Results 
 
The optimal controller is seen to provide, with no 
additional feedback an ideal, flat line glucose response 
for both a normal ICU feeding profile and an extreme 
case. The extreme case does lead to potential problems 
with the demand for negative insulin that would require 
an additional, uncorrected glucose infusion. However, 
this case is extreme and not representative of any 
accepted glucose feeding protocol for critical care 
patients in either rapidity of infusion, or total amount 
of calories given. In each case, the normal response 
was exceeded and tight, nearly perfect glucose control, 
which is very important for some classes of critical 
care patients, was maintained. 
 
 
5. Conclusions 
 
 
The emergence of glucose sensors capable of providing 
blood glucose readings at a very high rate is 
investigated along with the ability to automate insulin 
infusion for diabetic and hyperglycemic ICU patients. 
ICU patients present a special case where the feeding 
protocols tend to consist of infrequent, slow or uniform 
infusions of smaller amounts of glucose. As a result, 
the glucose input profile is a known and this data can 
be used to advantage. Although the optimal controller 
developed does not require feedback of the glucose 
value these sensors can be used for other forms of 
feedback as needed and to monitor patient response for 
safety. 
 
The optimal infusion control law developed is an 
entirely a function of patient parameters and the 
glucose input profile. For the slower infusions typically 
encountered in ICU patients the optimal control law 
can provide a nearly perfectly flat glucose response 
with no need for additional glucose infusion for 
stability. For more extreme tests, such as the multi-
meal test presented, some glucose infusion is 
necessary, however the glucose response curve remains 
flat. In both cases these ideal results outperform normal 
response, in addition to which ICU patients can often 
be hyperglycemic due to physiological stress even with 
no previous diabetic history.  Overall, an optimal 
control law has been developed and tight, nearly ideal 
glucose regulation shown for ICU scenarios where the 
glucose input is a known, slow-moving function. 
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